1. Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell Lung Cancer 
Alan Sandler, MD, Jing Yi, PhD, Suzanne Dahlberg, PhD, Margaret M. Kolb, DrPH, Lisa Wang, PhD, Julie Hambleton, MD, Joan Schiller, MD, David H. Johnson, MD 
Journal of Thoracic Oncology 
Volume 5, Issue 9, Pages (September 2010)
DOI: /JTO.0b013e3181da36f4
Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

2. FIGURE 1
Survival outcomes by histology type. A, Median OS and HR with forest plots are shown for PC- or PCB-treated NSCLC patients with different histology types. HRs are from unstratified models. B, Kaplan-Meier curves are shown for OS of patients with adenocarcinoma histology treated with PC or PCB; 12- and 24-month survival rates are indicated. C, Median PFS, described as for OS in (A). NSCLC, non-small cell lung cancer; NOS, not otherwise specified; PC, paclitaxel/carboplatin; PCB, paclitaxel/carboplatin + bevacizumab; OS, overall survival; HR, hazard ratio; PFS, progression-free survival.
Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181da36f4)
Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions